In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Oculis Holding, with a price target of $30.00. The company’s shares opened today at $17.86.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alkermes, and Arrowhead Pharmaceuticals. According to TipRanks, Gerberry has an average return of 8.8% and a 55.76% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oculis Holding with a $33.50 average price target.
The company has a one-year high of $23.08 and a one-year low of $13.60. Currently, Oculis Holding has an average volume of 15.82K.
Read More on OCS:
Disclaimer & DisclosureReport an Issue
- Oculis initiated with a Buy at Needham
- Nvidia reportedly stops H20 AI chip output for China: Morning Buzz
- Oculis price target raised to $33 from $32 at H.C. Wainwright
- Oculis Holding: Buy Rating Backed by Strong Financials and Promising Clinical Pipeline
- Oculis Holding AG Reports Q2 2025 Financial Progress
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)